Sector News

Deal-hungry Perrigo elbows aside competitors for Omega Pharma

October 30, 2014
Life sciences
Deal-hungry Perrigo is looking for more seats at the over-the-counter table, and the drugmaker may soon get its wish. The company is said to be close to sealing the deal for Belgian OTC maker Omega Pharma, inching past big-name competitors like Sanofi, Actavis and Boehringer Ingelheim.
 
As Bloomberg reports, the drugmaker has entered exclusive talks to purchase Omega Pharma for €4 billion ($5 billion), people familiar with the matter told the news outlet. The deal would deliver Perrigo some much-sought-after OTC clout, as the Belgian drugmaker boasts about 2,000 brands, including painkiller Solpadeine. Not to mention the company’s €1.2 billion ($1.6 billion) in sales last year thanks to standout performances in Europe and Russia–a 16% jump on the previous year’s numbers.
 
Perrigo is no stranger to M&A; the company snatched up Elan last July for $8.6 billion, shifting its domicile to Ireland to reap the benefits of a lower tax rate and expanding its footprint abroad.
 
And Perrigo is not the only one looking for more OTC firepower. Novartis and GlaxoSmithKline have agreed to launch a consumer health JV that could catapult the team to the number one spot in the market. Bayer picked up Merck’s consumer unit in May for $14.2 billion, outbidding the likes of Sanofi, Novartis and Reckitt Benckiser. The move is expected to create a business that generated $7.4 billion in combined 2013 sales, a “major milestone” on the company’s path toward global leadership in nonprescription medicines, Bayer CEO Marjin Dekkers said at the time of the deal.
 
Meanwhile, some pharma M&A has stalled, thanks to new U.S. guidelines making it more difficult for companies to move abroad for tax-paying purposes. Earlier this month, Salix Pharmaceuticals dropped its tax inversion deal for Cosmo Pharmaceuticals, and AbbVie called off its pending $55 billion deal for Dublin-based Shire.
 
By Emily Wasserman
 

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.